Tivic Health Expands Intellectual Property Portfolio
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has expanded its intellectual property portfolio with three new patents granted in the US and Europe. The patents protect:
1. Adaptive trigger technology for microcurrent stimulation devices
2. Methods to identify preferred treatment points
3. Dynamic adjustment of stimulation voltage during treatment
These innovations enhance device performance, comfort, and user experience. Blake Gurfein, Chief Scientific Officer, emphasized the company's commitment to building a robust IP portfolio for current and future products, including non-invasive vagus nerve stimulation assets.
Tivic Health Systems, Inc. (Nasdaq: TIVC), un'azienda di medicina bioelettronica, ha ampliato il suo portafoglio di proprietà intellettuale con tre nuovi brevetti concessi negli Stati Uniti e in Europa. I brevetti proteggono:
1. Tecnologia di attivazione adattativa per dispositivi di stimolazione a microcorrente
2. Metodi per identificare i punti di trattamento preferiti
3. Regolazione dinamica della tensione di stimolazione durante il trattamento
Queste innovazioni migliorano le prestazioni del dispositivo, il comfort e l'esperienza dell'utente. Blake Gurfein, Chief Scientific Officer, ha sottolineato l'impegno dell'azienda a costruire un solido portafoglio di proprietà intellettuale per i prodotti attuali e futuri, compresi gli asset di stimolazione non invasiva del nervo vago.
Tivic Health Systems, Inc. (Nasdaq: TIVC), una empresa de medicina bioelectrónica, ha ampliado su portafolio de propiedad intelectual con tres nuevas patentes otorgadas en EE. UU. y Europa. Las patentes protegen:
1. Tecnología de activación adaptativa para dispositivos de estimulación de microcorriente
2. Métodos para identificar los puntos de tratamiento preferidos
3. Ajuste dinámico del voltaje de estimulación durante el tratamiento
Estas innovaciones mejoran el rendimiento del dispositivo, la comodidad y la experiencia del usuario. Blake Gurfein, Director Científico, enfatizó el compromiso de la empresa de construir un sólido portafolio de propiedad intelectual para los productos actuales y futuros, incluidos los activos de estimulación no invasiva del nervio vago.
Tivic Health Systems, Inc. (Nasdaq: TIVC), 생체전자 의학 회사,는 미국과 유럽에서 새로운 세 가지 특허를 부여받아 지적 재산 포트폴리오를 확대했습니다. 이 특허는 다음을 보호합니다:
1. 미세 전류 자극 장치를 위한 적응형 트리거 기술
2. 선호하는 치료 지점을 식별하는 방법
3. 치료 중 자극 전압의 동적 조정
이 혁신은 장치 성능, 편안함 및 사용자 경험을 향상시킵니다. 블레이크 거르핀 최고 과학 책임자는 현재 및 미래의 제품을 위한 강력한 지적 재산 포트폴리오를 구축하겠다는 회사의 의지를 강조했습니다. 여기에는 비침습적 미주 신경 자극 자산이 포함됩니다.
Tivic Health Systems, Inc. (Nasdaq: TIVC), une entreprise de médecine bioélectronique, a élargi son portefeuille de propriété intellectuelle avec trois nouveaux brevets accordés aux États-Unis et en Europe. Les brevets protègent :
1. Technologie de déclenchement adaptatif pour dispositifs de stimulation à microcourant
2. Méthodes pour identifier les points de traitement préférés
3. Ajustement dynamique de la tension de stimulation pendant le traitement
Ces innovations améliorent les performances des dispositifs, le confort et l'expérience utilisateur. Blake Gurfein, Directeur Scientifique, a souligné l'engagement de l'entreprise à construire un solide portefeuille de propriété intellectuelle pour les produits actuels et futurs, y compris les actifs de stimulation non invasive du nerf vague.
Tivic Health Systems, Inc. (Nasdaq: TIVC), ein Unternehmen für bioelektronische Medizin, hat sein intellektuelles Eigentum mit drei neuen Patenten, die in den USA und Europa erteilt wurden, erweitert. Die Patente schützen:
1. Adaptive Trigger-Technologie für Mikrostimulationsgeräte
2. Methoden zur Identifizierung bevorzugter Behandlungsstellen
3. Dynamische Anpassung der Stimulationsspannung während der Behandlung
Diese Innovationen verbessern die Geräteleistung, den Komfort und die Benutzererfahrung. Blake Gurfein, Chief Scientific Officer, betonte das Engagement des Unternehmens, ein robustes IP-Portfolio für aktuelle und zukünftige Produkte, einschließlich nicht-invasiver Vagusnerv-Stimulationsmittel, aufzubauen.
- Expansion of intellectual property portfolio with three new patents
- Patents granted in both US and European markets
- Technology improvements for device performance and user experience
- Commitment to developing IP for current and future products
- None.
Tivic Health's recent patent grants represent a strategic step forward in the domain of bioelectronic medicine. These patents not only solidify Tivic's technological foundation but also provide a competitive edge in a rapidly evolving market.
The patent titled 'Adaptive Trigger For a Microcurrent Stimulation Device' underlines Tivic's focus on device optimization and user experience. This technology allows for the identification of preferred treatment points, enhancing the effectiveness and ease of use of the device. By programming triggers in various ways, the company ensures that the devices are adaptable and can cater to different user needs seamlessly.
Another significant patent, 'Sinus Treatment Device With Adaptive Circuit', showcases Tivic's commitment to personalized medicine. This technology adjusts the stimulation voltage dynamically during the treatment phase, thus maximizing comfort and performance. Personalized treatment is a growing trend in healthcare and Tivic is well-positioned to leverage this trend.
The announcement of these new patents is timely and strategic for Tivic Health. From a market perspective, adding patents for unique and dynamic features strengthens Tivic's intellectual property portfolio, which could translate into a competitive advantage and protect against potential infringements by competitors.
By securing these patents in both the US and Europe, Tivic Health also demonstrates a proactive approach to expanding its market reach. This dual-region coverage ensures that Tivic can operate freely within significant markets without the immediate threat of competition replicating their innovations.
Investors and stakeholders should note that robust intellectual property can enhance a company's valuation and market position. These patents could potentially lead to more partnership opportunities or even attract interest from larger healthcare firms looking to acquire cutting-edge technology.
The granting of new patents is a positive signal for Tivic Health's future financial health. Patents are a valuable asset and these recent additions could translate into increased revenue streams through product sales, licensing deals, or strategic partnerships.
In the short term, these patents may not immediately impact Tivic's financials but could lead to long-term benefits. Enhanced device performance and user experience can result in higher customer satisfaction and retention, thereby potentially increasing sales.
Moreover, as Tivic continues to innovate and protect its technology, it could also see a reduction in competition, which can further stabilize its market share and open avenues for scaling its operations efficiently.
Three New Patents Granted in the US and
- US Patent 12,011,592 and European Patent EP3615133, both titled “Adaptive Trigger For a Microcurrent Stimulation Device”, protect device and methods that the company uses to identify preferred treatment points and trigger a treatment mode. Triggers can be programmed in various ways to improve device performance and ease of use.
- European Patent EP3615134 entitled “Sinus Treatment Device With Adaptive Circuit” protects the device and methods that the company uses to dynamically adjust the stimulation voltage that is applied during a treatment phase, allowing for dynamic personalization of treatment. The dynamic changes in stimulation help to maximize comfort, enhance device performance, and enrich user experience.
“The adaptive design and personalization of treatment parameters are unique features of our intellectual property that make our existing product line effective, comfortable and easy to use,” commented Blake Gurfein, Chief Scientific Officer. “We are committed to continuing to build a robust intellectual property portfolio supporting both current and future products, including our emerging assets in non-invasive vagus nerve stimulation.”
About Tivic Health
Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding the future development of ncVNS treatment, the Tivic Health’s ability to commercialize products arising out of the ncVNS treatment and the Tivic Health’s plans to seek regulatory approval for such clinical products and Tivic Health’s continued focus on developing ncVNS treatment, including in the epilepsy, post-traumatic stress disorder, and/or ischemic stroke space; expected clinical utility including which patient populations may be pursued; market and other conditions; supply chain constraints; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic Health’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health’s actual results to differ from those contained in the forward-looking statements, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723691277/en/
Media Contact:
Morgan Luke
Morgan.Luke@tivichealth.com
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Source: Tivic Health Systems, Inc.
FAQ
What new patents has Tivic Health (TIVC) been granted?
How do Tivic Health's (TIVC) new patents improve their products?
What future technologies is Tivic Health (TIVC) developing?
